Cyclin-dependent kinases as downstream targets of oestrogen action: Potential prognostic indicators and therapeutic targets

Endocrine-Related Cancer

Volumn 4, Issue 3, 1997, Pages 357-370

  Sutherland, R L ^a   Prall, O W J ^a   Alle, K M ^a   Wilcken, N R C ^a   Hui, R ^a   Ball, J R ^a   Sarcevic, B ^a   Henshall, S M ^a   Musgrove, E A ^a   Watts, C K W ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; ESTRADIOL; ESTROGEN; OLOMOUCINE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE PHASE; DRUG TARGETING; HUMAN; NONHUMAN; PROGNOSIS; REVIEW;

EID: 8544283044     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0040357     Document Type: Review

References (60)

1. Abraham RT, Acquarone M, Andersen A, Asensi A, Belle R, Berger F, Bergounioux C, Brunn G, Buquet FC, Fagot D, Glab N, Goudeau H, Goudeau M, Guerrier P, Houghton P, Hendricks H, Kloareg B, Lippai M, Marie D, Maro B, Meijer L, Mester J, Mulner-Lorillon O, Poulet SA, Schierenberg E, Schutte B, Vaulot D & Verlhac MH 1995 Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biology of the Cell 83 105-120.
2. Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogens 12 2315-2324.
3. Bartkova J 1994 Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. Journal of Pathology 172 237-245.
4. Bartkova J, Lukas J, Müller H, Lützhøft D, Strauss M & Bartek J 1994 Cyclin D1 protein expression and function in human breast cancer. International Journal of Cancer 57 353-361.
5. Bartkova J, Lukas J, Strauss M & Bartek J 1995 Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10 775-778.
6. Beatson G 1896 On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet ii 104-107.
7. Berns E, Foekens J, van Staveren I, van Putten W, de Koning H, Portengen H & Klijn J 1995 Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159 11-18.
8. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW & Adams JM 1994 Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO Journal 13 2124-2130.
9. Borg A, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Olsson H, Killander D & McGurie WL 1991 Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. British Journal of Cancer 63 136-142.
10. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA & Sutherland RL 1993 Expression and amplification of cyclin genes in human breast cancer. Oncogene 8 2127-2133.
11. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D & Peters G 1995 Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Letters 90 43-50.
12. Dubik D & Shiu RPC 1988 Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. Journal of Biological Chemistry 263 12705-12708.
13. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339 1-15 and 71-85.
14. Fantl V, Smith R, Brookes S, Dickson C & Peters G 1993 Chromosome 11q13 abnormalities in human breast cancer. Cancer Surveys 18 77-94.
15. Fantl V, Stamp G, Andrews A, Rosewell I & Dickson C 1995 Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes and Development 9 2364-2372.
16. Foster JS & Wimalasena J 1996 Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Molecular Endocrinology 10 488-498.
17. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D & Peters G 1994 Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Research 54 1812-1817.
18. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G & Barnes D 1996 Cyclin D1 and prognosis in breast cancer. International Journal of Cancer 69 92-99.
19. Henderson B, Ross R & Bernstein L 1988 Estrogens as a cause of human cancer the Richard and Hinda Rosenthal Foundation Award lecture. Cancer Research 48 246-253.
20. Hinds PW, Dowdy SF, Eaton EN, Arnold A & Weinberg RA 1994 Function of a human cyclin gene as an oncogene. Proceedings of the National Academy of Sciences of the USA 91 709-713.
21. Hui R, Cornish AL, McClelland RA, Robertson JFR, Blarney RW, Musgrove EA, Nicholson RI & Sutherland RL 1996 Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clinical Cancer Research 2 923-928.
22. Jordan VC & Murphy CS 1991 Endocrine pharmacology of antioestrogens as antitumour agents. Endocrine Reviews 11 578-610.
23. Katzenellenbogen BS 1991 Antioestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. Journal of the National Cancer Institute 83 1434-1435.
24. Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A & Peters G 1991 D11S287, a putative oncogene on chromosome 11q13 is amplified and overexpressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6 439-444.
25. 1 phase population. Journal of Cellular Biochemistry 34 213-225.
26. Lovec H, Sewing A, Lucibello FC, Muller R & Moroy T 1994a Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9 323-326.
27. Lovec H, Grzeschiczek A, Kowalski MB & Moroy T 19946 Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO Journal 13 3487-3495.
28. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TWJ & Horne CHW 1995 Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11 885-891.
29. Matsushime H, Roussel MF, Ashmun RA & Sherr CJ 1991 Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65 701-713.
30. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R & Peterse J 1996 A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. British Journal of Cancer 73 728-734.
31. Morgan DO 1994 Principles of CDK regulation. Nature 374 131-134.
32. Musgrove EA, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW & Sutherland RL 1993 Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Molecular and Cellular Biology 13 3577-3587.
33. 1 to complete the cell cycle. Proceedings of the National Academy of Sciences of the USA 91 8022-8026.
34. Musgrove EA, Hui R, Sweeney KJE, Watts CKW & Sutherland RL 1996a Cyclins and breast cancer. Journal of Mammary Gland Biology and Neoplasia 1 153-162.
35. Musgrove EA, Sarcevic B & Sutherland RL 1996b Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for CDK2 activation and pRB hyperphosphorylation. Journal of Cellular Biochemistry 60 363-378.
36. Pearson O, West D, Hollander V & Treves N 1954 Evaluation of endocrine therapy for advanced breast cancer. Journal of the American Medical Association 154 234-239.
37. Peters G, Fantl V, Smith R, Brookes S & Dickson C 1995 Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Research and Treatment 33 125-135.
38. 1S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk-2. Journal of Biological Chemistry 272 10882-10894.
39. Riley DJ, Lee EY-HP & Lee W-H 1994 The retinoblastoma protein: more than a tumor suppressor. Annual Review of Cell Biology 10 1-29.
40. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N & Schmidt EV 1993 Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Molecular and Cellular Biology 13 7358-7363.
41. Said TK, Luo L & Medina D 1996 Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclin D1 and D2 binding to Cdk4. Carcinogenesis 16 2507-2513.
42. Seshadri R, Lee CSL, Hui R, McCaul K, Horsfall DJ & Sutherland RL 1996 Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clinical Cancer Research 2 1177-1184.
43. 1 cyclins. Cell 73 1059-1065.
44. Sherr CJ 1995 D-type cyclins. Trends in Biological Sciences 20 187-190.
45. Sherr CJ & Roberts JM 1995 Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Development 9 1149-1163.
46. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ & Weinberg RA 1995 Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82 621-630.
47. Soule HD & McGrath CM 1980 Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Letters 10 177-189.
48. Sutherland RL, Reddel RR & Green MD 1983a Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. European Journal of Cancer and Clinical Oncology 19 307-318.
49. Sutherland RL, Hall RE & Taylor IW 1983b Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Research 43 3998-4006.
50. Sweeney KJE, Musgrove EA, Watts CKW & Sutherland RL 1996 Cyclins and breast cancer. In Mammary Tumor Cell Cycle. Differentiation and Metastasis, pp 141-170. Eds R Dickson & M Lippman. Boston: Kluwer Academic Publishers.
51. Taylor IW, Hodson PJ, Green MD & Sutherland RL 1983 Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Research 43 4007-4010.
52. Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME & Dickson RB 1989 ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Research 49 6929-6934.
53. Wakeling AE, Dukes M & Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Research 51 3867-3873.
54. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A & Schmidt EV 1994 Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369 669-671.
55. Watts CKW, Brady A, Sarcevic B, deFazio A, Musgrove EA & Sutherland RL 1995 Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Molecular Endocrinology 9 1804-1813.
56. Weinberg RA 1995 The retinoblastoma protein and cell cycle control. Cell 81 323-330.
57. Weinstat-Saslow D, Merino MJ, Marrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL & Steeg PS 1996 Overexpression of cyclin D1 distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Medicine 1 1257-1260.
58. Wilcken NRC, Prall OWJ, Musgrove EA & Sutherland RL 1997 Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clinical Cancer Research (In Press).
59. Zhang SY, Caamano J, Cooper F, Guo X & Klein-Szanto AJ 1994 Immunohistochemistry of cyclin D1 in human breast cancer. American Journal of Clinical Pathology 102 695-698.
60. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner LC, Schmidt EV & Arnold A 1995 Cyclin D1 (PRAD1) protein expression in breast cancer. Modern Pathology 8 560-567.